BBOT (BridgeBio Oncology Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by BBOT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-07-06 | Marc Cobo | Principal Accounting Officer | F | — | — |
| 2026-07-06 | Yong Ben | Chief Med & Dev Officer | F | — | — |
| 2026-07-06 | Pedro Beltran | President and CEO | F | — | — |
| 2026-07-06 | Bihua Chen | Director | J | — | — |
| 2026-07-06 | Idan Elmelech | COO & Principal Financial Ofcr | F | — | — |
| 2026-06-18 | Raymond J. Kelleher | Director | A | — | — |
| 2026-06-18 | Peter F Lebowitz | Director | A | — | — |
| 2026-06-18 | Bihua Chen | Director | A | — | — |
| 2026-06-18 | Jake Bauer | Director | A | — | — |
| 2026-06-18 | FRANK MCCORMICK | Director | A | — | — |
| 2026-06-18 | Neil Kumar | Director | A | — | — |
| 2026-06-18 | Praveen P. Tipirneni | Director | A | — | — |
| 2026-05-12 | Pedro Beltran | President and CEO | A | — | — |
| 2026-05-12 | Idan Elmelech | COO & Principal Financial Ofcr | A | — | — |
| 2026-05-05 | Pedro Beltran | President and CEO | F | — | — |
| 2026-05-05 | Yong Ben | Chief Med & Dev Officer | F | — | — |
| 2026-05-05 | Uneek Mehra | — | F | — | — |
| 2026-03-26 | Peter F Lebowitz | Director | A | — | — |
| 2026-03-12 | Uneek Mehra | Chief Financial Officer | A | — | — |
| 2026-03-12 | Pedro Beltran | Chief Scientific Officer | A | — | — |
| 2026-03-12 | Yong Ben | Chief Med & Dev Officer | A | — | — |
| 2026-01-05 | Eli M. Wallace | Chief Executive Officer | A | — | — |
| 2025-12-12 | Eli M. Wallace | Chief Executive Officer | D | — | — |
| 2025-10-16 | BridgeBio Pharma, Inc. | 10%+ Owner | J | — | — |
| 2025-10-06 | Eli M. Wallace | Chief Executive Officer | A | — | — |
| 2025-08-28 | Eli M. Wallace | Chief Executive Officer | A | — | — |
| 2025-08-28 | Uneek Mehra | Chief Financial Officer | A | — | — |
| 2025-08-28 | Praveen P. Tipirneni | Director | A | — | — |
| 2025-08-28 | Yong Ben | Chief Med & Dev Officer | A | — | — |
| 2025-08-28 | Pedro Beltran | Chief Scientific Officer | A | — | — |
| 2025-08-28 | FRANK MCCORMICK | Director | A | — | — |
| 2025-08-28 | Jake Bauer | Director | A | — | — |
| 2025-08-13 | Bihua Chen | Director | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 14,589,846 | — |
| — | Director | 1,905,046 | — |
| — | Chief Med & Dev Officer | 44,576 | — |
| — | President and CEO | 44,576 | — |
| — | Chief Financial Officer | 22,806 | — |
| — | COO & Principal Financial Ofcr | 14,495 | — |
| — | Principal Accounting Officer | 5,306 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BBOT quote page; the site-wide leaderboard is on the insider transactions hub.